All News
Filter News
Found 10,129 articles
-
Nomination Committee Appointed in Respect of AGM 2020 in Oncopeptides
10/10/2019
According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on May 21st, 2019, the Nomination Committee for the annual general meeting 2020 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30th,
-
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2019
10/10/2019
Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group's financial figures.
-
bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
10/9/2019
bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including haemophilia.
-
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
10/8/2019
Merck KGaA, Darmstadt, Germany Designates Undisclosed Bispecific ADC as Clinical Development Candidate
-
XPOVIO™ (selinexor) Now Available to Excelera Network Members for Treatment of Relapsed or Refectory Multiple Myeloma
10/8/2019
As part of the innovative treatments offered through the Excelera Network, members granted immediate access to XPOVIO upon the treatment's accelerated FDA approval in July 2019
-
OWC Pharmaceutical Research Corp. to Report Top Line Results (TLR) for a Safety Study on Its Cannabis-based Tablets
10/7/2019
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today that, on September 25, 2019, One World Cannabis Ltd., a company organized and existing under the laws of Israel and a wholly-owned subsidiary of OWC received Top Line Results
-
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
10/4/2019
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma.
-
The company plans to use the funds raised to advance the ARC-T and sparX programs, including development of a bivalent BCMA-targeted therapy in multiple myeloma and a CD123-targeted treatment in acute myeloid leukemia.
-
OncLive® Reveals the 2019 Innovative Technology in Cancer Care Challenge Finalists
10/3/2019
OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with the most current and insightful information they need to offer the best patient care, has named the six finalists of the OncLive® Innovation Challenge: Innovative Technology in Cancer Care
-
Myeloma Canada Proudly Appoints 5 New Directors to its Board
10/3/2019
Myeloma Canada is delighted to announce that five leaders within the Canadian community have joined its Board of Directors.
-
Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
10/3/2019
Cirmtuzumab combination demonstrated clinical activity with complete responses in mantle cell lymphoma
-
WWE® And The Leukemia & Lymphoma Society (LLS) Join Forces To Help Cancer Patients And Families
10/3/2019
New Partnership Supports LLS's Children's Initiative to address the urgent need for new and better treatments for pediatric cancer patients
-
Heidelberg Pharma AG Announces Adjustment of Guidance
10/2/2019
Heidelberg Pharma AG announced that it has adjusted its guidance for the current fiscal year published in March 2019.
-
NMPA Approves IND Application for CT103A, a Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Biologics
10/2/2019
IASO Biotherapeutics announced that IASO BIO has received National Medical Products Administration approval for an Investigational New Drug Application for CT103A—an innovative therapy for the treatment of relapsed refractory multiple myeloma patients.
-
The Myeloma Crowd Launches Psoriasis / Multiple Myeloma Study Using Its HealthTree® Platform
10/2/2019
HealthTree IRB-Approved Data Study to Identify Potential Correlations Between Diseases
-
Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
10/2/2019
KEYTRUDA is First Anti-PD-1 Therapy Approved as Monotherapy and in Combination with Chemotherapy in First-Line Setting for NSCLC in China
-
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates
10/1/2019
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), and Lonza (SWX: LONN), announced today that the companies have entered into a manufacturing service agreement covering clinical manufacturing of Cellectis’ allogeneic UCART product candidates targeting hematological malignancies.
-
AmerisourceBergen Selected by Karyopharm to Support XPOVIO™
10/1/2019
New rare disease therapy supported by AmerisourceBergen’s unified offerings including specialty pharmacy dispensing, distribution services, 3PL and community oncology services
-
A new blood test in development from GRAIL, Inc. and studied by investigators at the Dana-Farber Cancer Institute has the ability to accurately screen for numerous types of cancer.
-
Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer
9/30/2019
Opdivo demonstrated a 23% reduction in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy